



Avita Announces Office Transitions in Australia and the UK

November 29, 2017

Decision Optimizes Access to Strategic Markets to Support Long-Term Growth Strategy

Valencia, CA, USA, Perth, Australia and London, United Kingdom, 29 November 2017 —Avita Medical (ASX: [AVH](#), OTCQX: [AVMXY](#)), a regenerative medicine company with a platform technology creating opportunities in burn and wound care, and applications in aesthetics indications, announced today the relocation of two of its offices. The Perth office will be relocating to the east coast of Australia, while the Wimbledon office will be moving to a more strategic location in the EU.

"The decision to transition these two office locations is part of our global commercialization strategy, which includes re-aligning our priorities and resources in advance of our anticipated approval of ReCell® in the United States," said Dr. Mike Perry, CEO, Avita Medical. "ReCell® has the potential to be the leading platform in regenerative medicine for skin, given its proposed indication and additional efforts underway across multiple therapeutic opportunities, and we are committed to putting the right resources in place to ensure successful commercialization of our platform."

The premarket approval (PMA) application for the ReCell® device was filed September 28, 2017, and is currently under review by the U.S. Food and Drug Administration (FDA).

"As a global company, relocating these two offices allows us to be strategically located closer to the market, allowing for optimal access and better positioning the company to support our long-term growth strategy and objectives," said Erin Liberto, Chief Commercial Officer. "We are committed to developing innovative technologies for our patients, and look forward to making a truly meaningful difference in their lives."

###

ABOUT AVITA MEDICAL LIMITED

Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient's own skin. Our medical devices work by preparing a Regenerative Epithelial Suspension (RES™), an autologous suspension comprised of the patients' own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This is then applied to the area to be treated.

In all countries outside of Europe, our portfolio is marketed under the ReCell® brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics.

ReCell® is TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. ReCell® is designed for the treatment of burns and plastic reconstructive procedures; ReGenerCell™ has been formulated for chronic wounds including leg and foot ulcers; and ReNovaCell™ is tailored for aesthetic applications including the restoration of pigmentation.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company's control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

###

FOR FURTHER INFORMATION:

Australia

Monsoon Communications

Sarah Kemter

USA

INC Research/inVentiv Health

Deb Kazenelson

Phone: +61 (0)3 9620 3333

Mobile: +61 (0)407 162 530

sarahk@monsoon.com.au

Phone: +1 (310) 309-1043

Deborah.kazenelsondeane@inventivhealth.com

Avita Medical Ltd

Tim Rooney

Chief Financial Officer

Phone +1 (661) 367-9161

trooney@avitamedical.com